Cargando…

Gastroenterologists Adherence to Tumor Necrosis Factor Antagonist Combination Therapy in Inflammatory Bowel Disease

Introduction: Tumor necrosis factor antagonists (anti-TNF) therapies are used for the management of moderate to severe inflammatory bowel disease (IBD). Anti-TNF combination therapy, with immunomodulators, has been shown to reduce immunogenicity, especially for infliximab, improve treatment success...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abdullah, Israa, Alhendi, Ghadeer, Alhadab, Anwar, Alasfour, Hajer, Shehab, Mohammad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511459/ https://www.ncbi.nlm.nih.gov/pubmed/34660635 http://dx.doi.org/10.3389/fmed.2021.725512

Ejemplares similares

Relationship Between Patient Sex and Serum Tumor Necrosis Factor Antagonist Drug and Anti-drug Antibody Concentrations in Inflammatory Bowel Disease; A Nationwide Cohort Study
por: Shehab, Mohammad, et al.
Publicado: (2021)

Impact of tumor necrosis factor antagonist combination and anti-integrin therapies on body mass index in inflammatory bowel disease: A cross-sectional study
por: Shehab, Mohammad, et al.
Publicado: (2023)

Impact of biologics and small molecules for inflammatory bowel disease on COVID‐19‐related hospitalization and mortality: A systematic review and meta‐analysis
por: Alrashed, Fatema, et al.
Publicado: (2022)

Effectiveness of vedolizumab and ustekinumab as second biologic agent in achieving target outcomes in tumor necrosis factor antagonists experienced patients with inflammatory bowel disease (enroll-ex study)
por: Alrashed, Fatema, et al.
Publicado: (2023)

Variations in the medical treatment of inflammatory bowel disease among gastroenterologists
por: Singh, Shailendra, et al.
Publicado: (2018)

Methotrexate in inflammatory bowel disease: A primer for gastroenterologists
por: AlAmeel, Turki, et al.
Publicado: (2022)

Effectiveness of Dual Biologic or Small Molecule Therapy for Achieving Endoscopic Remission in Refractory Inflammatory Bowel Disease
por: Abdullah, Israa, et al.
Publicado: (2022)

Impact of BNT162b2 mRNA Vaccination on the Development of Short and Long-Term Vaccine-Related Adverse Events in Inflammatory Bowel Disease: A Multi-Center Prospective Study
por: Shehab, Mohammad, et al.
Publicado: (2022)

The Emerging Adult with Inflammatory Bowel Disease: Challenges and Recommendations for the Adult Gastroenterologist
por: Trivedi, Itishree, et al.
Publicado: (2015)

Gastroenterologists’ Views of Shared Decision Making for Patients with Inflammatory Bowel Disease
por: Siegel, Corey A., et al.
Publicado: (2015)

Variation in Inflammatory Bowel Disease Care among Saudi Pediatric Gastroenterologists
por: Al-Sarkhy, Ahmed A.
Publicado: (2017)

Impact of medical therapies for inflammatory bowel disease on the severity of COVID-19: a systematic review and meta-analysis
por: Alrashed, Fatema, et al.
Publicado: (2021)

Insufficient Knowledge of Korean Gastroenterologists Regarding the Vaccination of Patients with Inflammatory Bowel Disease
por: Jung, Yoon Suk, et al.
Publicado: (2014)

Medication-Related Burden and Medication Adherence Among Geriatric Patients in Kuwait: A Cross-Sectional Study
por: Awad, Abdelmoneim, et al.
Publicado: (2020)

Split-dose bowel preparation improves adequacy of bowel preparation and gastroenterologists’ adherence to National Colorectal Cancer Screening and Surveillance Guidelines
por: Menees, Stacy Bartnik, et al.
Publicado: (2018)

Perspectives on endoscopic surveillance of dysplasia in inflammatory bowel disease: a survey of academic gastroenterologists
por: Gallinger, Zane R., et al.
Publicado: (2017)

Very Early-Onset Inflammatory Bowel Disease: A Challenging Field for Pediatric Gastroenterologists
por: Arai, Katsuhiro
Publicado: (2020)

Attitudes and Knowledge of Australian Gastroenterologists Around the Use of Medicinal Cannabis for Inflammatory Bowel Disease
por: Benson, Melissa J, et al.
Publicado: (2020)

Immunogenicity of BNT162b2 Vaccine Booster Dose in Patients With Inflammatory Bowel Disease Receiving Infliximab Combination Therapy: A Prospective Observational Study
por: Shehab, Mohammad, et al.
Publicado: (2022)

Bridges to excellence quality indicators in inflammatory bowel disease (IBD): differences between IBD and non-IBD gastroenterologists
por: Bilal, Mohammad, et al.
Publicado: (2017)

Don’t Forget the Doctor: Gastroenterologists’ Preferences on the Development of mHealth Tools for Inflammatory Bowel Disease
por: van Mierlo, Trevor, et al.
Publicado: (2015)

A cross-sectional survey of Saudi gastroenterologists: Transition strategies for adolescents with inflammatory bowel disease
por: Al-Jahdali, Elaf, et al.
Publicado: (2017)

Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
por: Marsal, Jan, et al.
Publicado: (2022)

Transition care in inflammatory bowel disease: A needs assessment survey of Quebec gastroenterologists and allied nurses
por: Strohl, Matthew, et al.
Publicado: (2017)

Taking a JAB at How Gastroenterologists Can Increase Vaccination Rates in Patients with Inflammatory Bowel Disease
por: Almasry, Mazen, et al.
Publicado: (2023)

SARS-CoV-2 vaccine acceptance among gastroenterologists and inflammatory bowel disease patients: VACUNEII project
por: Ferreiro-Iglesias, Rocío, et al.
Publicado: (2022)

SARS-CoV-2 vaccine acceptance among gastroenterologists and inflammatory bowel disease patients: VACUNEII project
por: Ferreiro-Iglesias, Rocío, et al.
Publicado: (2022)

Gastroenterologist-Lead Management of Iron Deficiency Anemia in Inflammatory Bowel Disease Is Effective, Safe, and May Increase Quality of Life
por: Coe, Christopher L, et al.
Publicado: (2020)

A Study on Differences between Professional Endoscopists and Gastroenterologists in Endoscopic Detection and Standard Pathological Biopsy of Inflammatory Bowel Diseases
por: Yang, Dong, et al.
Publicado: (2022)

Impact of treatment with immunomodulators and tumour necrosis factor antagonists on the incidence of infectious events in patients with inflammatory bowel disease
por: Andersson, Per, et al.
Publicado: (2022)

Comparative Outcomes and Safety of Vedolizumab vs Tumor Necrosis Factor Antagonists for Older Adults With Inflammatory Bowel Diseases
por: Singh, Siddharth, et al.
Publicado: (2022)

Predictors and optimal management of tumor necrosis factor antagonist nonresponse in inflammatory bowel disease: A literature review
por: Wang, Liang-Fang, et al.
Publicado: (2023)

The Prevalence of Adherent-Invasive Escherichia coli and Its Association With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis
por: Kamali Dolatabadi, Razie, et al.
Publicado: (2021)

Prognostication in inflammatory bowel disease
por: Spencer, Elizabeth A., et al.
Publicado: (2022)

Frequency of Positive Conversion of Interferon-Gamma Release Assay Results Among Patients With Inflammatory Bowel Disease Treated With Non-tumor Necrosis Factor Inhibitors
por: Kim, Kyuwon, et al.
Publicado: (2021)

A Combined Set of Four Serum Inflammatory Biomarkers Reliably Predicts Endoscopic Disease Activity in Inflammatory Bowel Disease
por: Bourgonje, Arno R., et al.
Publicado: (2019)

Endoscopic Retrieval of an Ingested Mobile Phone From the Stomach of a Prisoner: When Gastroenterologists Answer the Call
por: Ali, Ahmed, et al.
Publicado: (2022)

Intestinal Ultrasound for the Pediatric Gastroenterologist: A Guide for Inflammatory Bowel Disease Monitoring in Children: Expert Consensus on Behalf of the International Bowel Ultrasound Group (IBUS) Pediatric Committee
por: Kellar, Amelia, et al.
Publicado: (2022)

Contrasting Perspectives of Anesthesiologists and Gastroenterologists on the Optimal Time Interval between Bowel Preparation and Endoscopic Sedation
por: Agrawal, Deepak, et al.
Publicado: (2015)

The COVID-19 Pandemic and Post-Infection Irritable Bowel Syndrome: What Lies Ahead for Gastroenterologists
por: Chan, Walter W., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6e4epukg7brdiqemcbog6bllsj